Lana Pine

Both biologic-naïve and biologic-experience patients receiving guselkumab demonstrated significantly higher ACR20 when compared with ustekinumab.

Judith Ng-Cashin, MD discusses Novotech's recent Rheumatoid Arthritis - Global Clinical Trial Landscape report.

Test your knowledge of the ACR's guideline for the management of gout with this quiz!

John H Stone, MD, MPH, discusses the recent clinician-authored white paper from the Alliance for Patient Access: "Addressing Access Barriers for IgG4-RD Patients.”

A real-world cohort of patients with treatment-resistant active psoriatic arthritis receiving 6 months of guselkumab treatment achieved clinically meaningful improvements in pain and physical function.

After propensity score matching, patients with COVID-19 were at an increased risk for AIRD when compared with both uninfected controls and influenza-infected patients.

Jon Martin, US Commercial Lead of Biosimilars at Organon, discusses the decision to select biosimilar adalimumab-bwwd and its potential implications on the pharmaceutical market.

The drug is the first tocilizumab biosimilar with an FDA-approved intravenous and subcutaneous formulation.

Patients who were naïve to adalimumab tended to switch to other targeted therapies, while those who had been previously treated with adalimumab were more likely to switch back to the reference product.

The decision was based on clinical studies demonstrating no clinically meaningful differences between the biosimilar and its reference product.

The primary endpoint was achieved, with biosimilar CT-P41 demonstrating comparable pharmacokinetics.

The overall effect of psychological interventions on patients with fibromyalgia was -0.31 for depressive symptoms and -0.15 for anxiety symptoms, which were deemed statistically significant.

This month’s biosimilars month in review highlights the evolving landscape of biosimilars, emphasizing their potential benefits in terms of safety, cost-effectiveness, and increased treatment options, while recognizing the importance of addressing challenges in adoption and perception.

The rheumatology month in review highlights cognitive dysfunction in patients with fibromyalgia, explores the impact of obesity on treatment response in rheumatoid arthritis, and evaluates work-related challenges faced by patients with psoriatic arthritis.

A progressive and significant increase in the frequency of strong opioid consumers was observed over a 12-year period, increasing from 5.8% to 12.8%.

At week 24, patients with moderate to severe PsA receiving risankizumab had a significantly higher ACR20 response rate when compared with placebo.

No statistically significant differences in the odds of remission at ≤12 months were observed between patients receiving adalimumab compared with other biologics.

Patients perceived WelTel as a beneficial tool for providing quality care across domains including efficiency, safety, and patient-centeredness.

Continuous improvement across all MDA domains was demonstrated over the 100-week timeframe, with approximately 70% of patients achieving near remission in swollen joint count, enthesitis, and the Psoriasis Area and Severity Index (PASI).

The approval was based on clinical data from 3 multicenter, randomized trials which demonstrated the safety, efficacy, and biosimilarity of adalimumab-ryvk compared with the reference product.

At the 6-month mark, between 73.2% to 78.6% of Canadian patients with psoriatic arthritis reported pain.

b/tsDMARD treatment led to a mean relative improvement of 41% for total work productivity in patients with psoriatic arthritis.

Of those who received an infliximab biosimilar, 87.8% were maintained on a single biosimilar without the need to switch to an alternative product.

Findings provide insights into the current state of healthcare utilization for patients with gout living in South Korea.

Among patients aged 40 – 49 years, asymptomatic hyperuricemia was linked to incident arthritis.

The guidelines will help clinicians when applying imagine techniques for all common CiAs and include the full spectrum of imaging in clinical practice, including diagnosis, monitoring disease activity, treatment response, and the prediction of outcome.

When stratified by 2 groups (high exposure vs low exposure), a significant link between high PM10 exposure and mortality was observed among patients with RA-ILD.

Patients with fibromyalgia and cognitive dysfunction report feeling a loss of identify and impaired social interaction.

Results revealed a consistent safety profile with low rates of discontinuation and no increase in adverse events with prolonged treatment exposure in patients treated with ixekizumab.

Patients receiving a nursing intervention had significantly better response rates, improvements in anxiety and depression scores, and significantly higher patient satisfaction when compared with the conventional care group.